This CME program will cover data on new therapeutic strategies for the management of patients with relapsed-refractory multiple myeloma that were presented at the European Hematology Association 2016 Annual Congress in Copenhagen, Denmark on June 9 - 12, 2016. The expert faculty of this program will discuss tumor science, including relapsed, refractory, and progressive disease. They will discuss the analysis of clinical trial data and therapy options for the treatment of patients with multiple myeloma. This program will give physicians a better understanding of when to implement data-driven, patient-specific treatment plans to improve outcomes for patients with relapsed or refractory multiple myeloma.
Improve your hematology practice by taking one of Elsevier's complimentary continuing medical education courses.